Patient tolerance and acceptance of colesevelam hydrochloride: Focus on type-2 diabetes mellitus

P and T

Volumn 40, Issue 1, 2015, Pages 62-67

  Brunetti, Luigi ^a   Desantis, Evelyn Hermes ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; COLESEVELAM; EPICHLOROHYDRIN; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ARTICLE; BINDING AFFINITY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FLATULENCE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84921862417     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet2011;378(9785):31–40.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, Georgia: Centers for Disease Control and Prevention, 2011.
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care2013;36(4):1033–1046.
4. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care2011;34(6):1249–1257.
5. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract2010;87(3):293–301.
6. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol2008;18(3):222–229.
7. Jamous RM, Sweileh WM, Abu-Taha AS, et al. Adherence and satisfaction with oral hypoglycemic medications: a pilot study in Palestine. Int J Clin Pharm2011;33(6):942–948.
8. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract2013;19(2):327–336.
9. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care2004;27(5):1218–1224.
10. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2009;32(1):193–203.
11. Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One2012;7(3):e32412.
12. Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adher ence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Prefer Adherence2013;7:525–530.
13. Finucane TE. The dogma of “tight control”: beyond the limits of evidence. Arch Intern Med 2006;166(15):1671–1672; author reply, 1672.
14. Schoenthaler AM, Schwartz BS, Wood C, Stewart WF. Patient and physician factors associated with adherence to diabetes medications. Diabetes Educ2012;38(3):397–408.
15. Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract2010;87(2):204–210.
16. Takebayashi K, Aso Y, Inukai T. Role of bile acid sequestrants in the treatment of type 2 diabetes. World J Diabetes2010;1(5):146–152.
17. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA1984;251(3):351–364.
18. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil2009;16(1):1–9.
19. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol2008;93(1):27–42.
20. Brinton EA. Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation. Diabetes Obes Metab2008;10(11):1004–1011.
21. Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 1989;76(suppl 1):65–71; discussion, 71–74.
22. Shepherd J, Packard CJ, Bicker S, et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med1980;302(22):1219–1222.
23. Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol1991;40(suppl 1):S53–S58.
24. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs2007;67(10):1383–1392.
25. Osorio J. Diabetes: a closer look at the mechanisms of action of colesevelam in humans. Nat Rev Endocrinol2012;8(3):128.
26. Nwose OM, Jones MR. Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes2013;6:75–79.
27. Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol2012;59(2):198–205.
28. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol2006;68:159–191.
29. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov2009;8(5):369–385.
30. Kogire M, Gomez G, Uchida T, et al. Chronic effect of oral chole-styramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas1992;7(1):15–20.
31. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatol-ogy2010;52(4):1455–1464.
32. Smushkin G, Sathananthan M, Piccinini F, et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes2013;62(4):1094–1101.
33. Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid seques-trants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia2012;55(2):432–442.
34. Brunetti L, Campbell RK. Clinical efficacy of colesevelam in type 2 diabetes mellitus. J Pharm Pract2011;24(4):417–425.
35. Brunetti L, Hermes-Desantis ER. The role of colesevelam hydro-chloride in hypercholesterolemia and type 2 diabetes mellitus. Ann Pharmacother2010;44(7–8):1196–1206.
36. Rosenstock J, Fonseca VA, Garvey WT, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract2010;16(4):629–640.
37. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med2008;168(18):1975–1983.
38. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care2008;31(8):1479–1484.
39. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med2008;168(14):1531–1540.
40. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care2012;35(6):1364–1379.
41. Handelsman Y, Goldberg RB, Garvey WT, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract2010;16(4):617–628.
42. Hansen RA, Farley JF, Maciejewski ML, et al. Real-world utilization patterns and outcomes of colesevelam HCl in the GE electronic medical record. BMC Endocr Disord2013;13(1):24.
43. Goldfne AB, Fonseca VA, Jones MR, et al. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res2010;42(1):23–30.
44. Bell DS. Current status of diabetes treatment. South Med J2002;95(1):24–29.
45. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother2003;4(5):779–790.
46. Goldberg RB. Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam—a clinical perspective. Diabetes Metab Syndr Obes2009;2:11–21.
47. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes mellitus. Diabetes Care2009;32(5):834–838.
48. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med1995;332(17):1125–1131.
49. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA1998;279(18):1458–1462.
50. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterol-emia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch2006;73(5):277–284.
51. Suzuki T, Oba K, Igari Y, et al. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. J Diabetes Complications2012;26(1):34–39.
52. Kondo K, Kadowaki T. Colestilan monotherapy signifcantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study. Diabetes Obes Metab2010;12(3):246–251.
53. Rosenstock J, Hernandez-Triana E, Handelsman Y, et al. Clinical effects of colesevelam in Hispanic subjects with primary hyper-lipidemia and prediabetes. Postgrad Med2012;124(4):14–20.
54. Rosenstock J, Hernandez-Triana E, Handelsman Y, et al. Initial combination therapy with metformin plus colesevelam in drug-naive Hispanic patients with early type 2 diabetes. Postgrad Med2012;124(4):7–13.
55. Goldberg RB, Rosenson RS, Hernandez-Triana E, et al. Cole-sevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diab Vasc Dis Res2013;10(3):256–262.
56. Rigby S P, Handelsman Y, Lai YL, et al. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract2010;16(1):53–63.
57. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther2007;29(1):74–83.
58. Robinson M, Lamb CA, Bergin FG, Mansfeld JC. A survey of patient opinion regarding the tolerability of, adherence to and efficacy of colesevelam compared with cholestyramine in the treatment of diarrhoea following ileal resection in Crohn’s disease. Abstract P307. Presentation at the Eighth Congress of the European Crohn’s and Colitis Organisation, Vienna, Austria, February 14–16, 2013.
59. Wedlake L, Thomas K, Lalji A, et al. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther2009;31(11):2549–2558.
60. Ye X, Qian C, Liu J, St Peter WL. Lower risk of major cardiovascular events associated with adherence to colesevelam HCl. Pharmaco-therapy2013;33(10):1062–1070.
61. Insull W, Jr., Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc2001;76(10):971–982.
62. Eriksson M, Hadell K, Holme I, et al. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med1998;243(5):373–380.
63. Eraker SA, Kirscht J P, Becker MH. Understanding and improving patient compliance. Ann Intern Med1984;100(2):258–268.
64. Romanelli RJ, Leahy A, Jukes T, et al. Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia. Ann Pharmacother2013;47(10):1247–1252.
65. Jermendy G, Wittmann I, Nagy L, et al. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit2012;18(2):CR72–CR77.
66. Wolff JL, Starfeld B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. ArchIntern Med2002;162(20):2269–2276.
67. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life defcits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res2005;14(5):1311–1320.
68. Braulin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints2000;41:708–709.
69. Hanus M, Zhorov E. Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. J Pharm Sci2006;95(12):2751–2759.